Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation

Journal of Medicinal Chemistry

Volumn 53, Issue 5, 2010, Pages 2204-2214

  Carroll, F Ivy ^a   Blough, Bruce E ^a   Mascarella, S Wayne ^a   Navarro, Hernán A ^a   Eaton, J Brek ^b   Lukas, Ronald J ^b   Damaj, M Imad ^c  

^a RTI INTERNATIONAL   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (N CYCLOPENTYLAMINO) 3' BROMOPROPIOPHENONE; 2 (N CYCLOPENTYLAMINO) 3' FLUOROPROPIOPHENONE; 2 (N CYCLOPENTYLAMINO) 3' METHOXYPROPIOPHENONE; 2 (N CYCLOPENTYLAMINO) 3' METHYLPROPIOPHENONE; 2 (N CYCLOPENTYLAMINO) 3' NITROPROPIOPHENONE; 2 (N PYRROLIDINYL) 3' BROMOPROPIOPHENONE; 2 (N PYRROLIDINYL) 3' FLUOROPROPIOPHENONE; 2 (N PYRROLIDINYL) 3' METHOXYPROPIOPHENONE; 2 (N PYRROLIDINYL) 3' METHYLPROPIOPHENONE; 2 (N PYRROLIDINYL) 3' NITROPROPIOPHENONE; 2 (N TERT BUTYLAMINO) 3' METHOXYPROPIOPHENONE; 2 (N TERT BUTYLAMINO) 3' NITROPROPIOPHENONE; AMFEBUTAMONE; MONOAMINE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA1; NICOTINIC RECEPTOR ALPHA3BETA2; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR ALPHA4BETA4; UNCLASSIFIED DRUG;

AMINE TRANSPORT; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BEHAVIOR; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; NORADRENALIN UPTAKE; SMOKING CESSATION; TAIL FLICK TEST;

ANIMALS; CELL LINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITORY CONCENTRATION 50; KETONES; MALE; MICE; MICE, INBRED ICR; PAIN; RECEPTORS, NICOTINIC; SMOKING CESSATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949348035     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm9017465     Document Type: Article

References (32)

1. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER Package; World Health Organization: Geneva, 2008; p 15.
2. Centers for Disease Control and Prevention. Cigarette smoking among adults: United States, 2007. Morbidity Mortality Wkly. Rep. 2001, 56, 1157-1161.
3. Benowitz, N. L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 2008, 83, 531-541.
4. Lerman, C.; LeSage, M. G.; Perkins, K. A.; O'Malley, S. S.; Siegel, S. J.; Benowitz, N. L.; Corrigall, W. A. Translational research in medication development for nicotine dependence. Nat. Rev. Drug Discovery 2007, 6, 746-762.
5. Gotti, C.; Moretti, M.; Gaimarri, A.; Zanardi, A.; Clementi, F.; Zoli, M. Heterogeneity and complexity of native brain nicotinic receptors. Biochem. Pharmacol. 2007, 74, 1102-1111.
6. Rahman, S.; Lopez-Hernandez, G. Y.; Corrigall, W. A.; Papke, R. L. Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction. CNS Neurol. Disord.: Drug Targets 2008, 7, 422-441.
7. Adams, D. J.; Nutter, T. J. Calcium permeability and modulation of nicotinic acetylcholine receptor-channels in rat parasympathetic neurons. J. Physiol. (Paris) 1992, 86, 67-76.
8. Le Novere, N.; Zoli, M.; Changeux, J. P. Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur. J. Neurosci. 1996, 8, 2428-2439.
9. Goldner, F. M.; Dineley, K. T.; Patrick, J. W. Immunohistochemical localization of the nicotinic acetylcholine receptor subunit alpha6 to dopaminergic neurons in the substantia nigra and ventral tegmental area. NeuroReport 1997, 8, 2739-2742.
10. Exley, R.; Clements, M. A.; Hartung, H.; Mcintosh, J. M.; Cragg, S. J. Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 2008, 33, 2158-2166.
11. Corrigall, W. A.; Franklin, K. B.; Coen, K. M.; Clarke, P. B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 1992, 107, 285-289.
12. Brody, A. L.; Olmstead, R. E.; London, E. D.; Farahi, J.; Meyer, J. H.; Grossman, P.; Lee, G. S.; Huang, J.; Hahn, E. L.; Mandelkern, M. A. Smoking-induced ventral striatum dopamine release. Am. J. Psychiatry 2004, 161, 1211-1218.
13. Fant, R. V.; Buchhalter, A. R.; Buchman, A. C.; Henningfield, J. E. Pharmacotherapy for Tobacco Dependence. In Nicotine Psychopharmacology. Handbook of Experimental Pharmacology; Henningfield, J. E., London, E. D., Pogun, S., Eds.; Springer-Verlag: Berlin, 2009; Vol.192, p 487.
14. Gonzales, D.; Rennard, S. I.; Nides, M.; Oncken, C.; Azoulay, S.; Billing, C. B.; Watsky, E. J.; Gong, J.; Williams, K. E.; Reeves, K. R. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 2006, 296, 47-55.
15. Fryer, J. D.; Lukas, R. J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 1999, 288, 88-92.
16. Slemmer, J. E.; Martin, B. R.; Damaj, M. I. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 2000, 295, 321-327.
17. Harbeson, S. L. Propiophenone Derivatives. WIPO Patent WO/ 2009/105218, 2009.
18. Hadizadeh, F.; Ebrahimzadeh, M. A.; Hosseinzadeh, H.; MotamedShariaty, V.; Salami, S.; Bekhradnia, A. R. Antidepressant and antioxidant activities of some 2-benzoxazolinone derivatives as bupropion analogues. Pharmacologyonline 2009, 1, 331-335.
19. Foley, K. F.; Cozzi, N. V. Novel aminopropiophenones as potential antidepressants. Drug Dev. Res. 2003, 60, 252-260.
20. Miller, D. K.; Sumithran, S. P.; Dwoskin, L. P. Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. J. Pharmacol. Exp. Ther. 2002, 302, 1113-1122.
21. Mooney, M. E.; Sofuoglu, M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev. Neurother. 2006, 6, 965-981.
22. Paterson, N. E.; Balfour, D. J.; Markou, A. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur. J. Neurosci. 2007, 25, 3099-3108.
23. Reuben, M.; Boye, S.; Clarke, P. B. Nicotinic receptors modulating somatodendritic and terminal dopamine release differ pharmacologically. Eur. J. Pharmacol. 2000, 393, 39-49.
24. Makhay, M. M.; O'Donnell, J. M. Effects of antidepressants in rats trained to discriminate the beta-2 adrenergic agonist clenbuterol. Pharmacol., Biochem. Behav. 1999, 63, 319-324.
25. Carroll, F. I.; Blough, B.; Abraham, P.; Mills, A. C.; Holleman, J. A.; Wolckenhauer, S. A.; Decker, A. M.; Landavazo, A.; McElroy, K. T.; Navarro, H. A.; Gatch, M. B.; Foster, M. J. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J. Med. Chem. 2009, 52, 6768-6781.
26. Eshleman, A. J.; Carmolli, M.; Cumbay, M.; Martens, C. R.; Neve, K. A.; Janowsky, A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol. Exp. Ther. 1999, 289, 877-885.
27. Damaj, M. I.; Carroll, F. I.; Eaton, J. B.; Navarro, H. A.; Blough, B. E.; Mirza, S.; Lukas, R. J.; Martin, B. R. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol. 2004, 66, 675-682.
28. Salas, R.; Sturm, R.; Boulter, J.; De Biasi, M. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J. Neurosci. 2009, 29, 3014-3018.
29. Lukas, R. J.; Fryer, J. D.; Eaton, J. B.; Gentry, C. L. Some Methods for Studies of Nicotinic Acetylcholine Receptor Pharmacology. In Nicotinic Receptors and the Nervous System; Levin, E. D., Ed.; CRC Press: Boca Raton, FL, 2002; pp 3-27.
30. Eaton, J. B.; Peng, J. H.; Schroeder, K. M.; George, A. A.; Fryer, J. D.; Krishnan, C.; Buhlman, L.; Kuo, Y. P.; Steinlein, O.; Lukas, R. J. Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EPl human epithelial cells. Mol. Pharmacol. 2003, 64, 1283-1294.
31. Gentry, C. L.; Lukas, R. J. Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes. J. Pharmacol. Exp. Ther. 2001, 299, 1038-1048.
32. D'Amour, F. E.; Smith, D. L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 1941, 72, 74-79.